Meeting highlights: International consensus panel on the treatment of primary breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 18, 2001, Pages 3817-3827

  Goldhirsch, A ^a   Glick, J H ^a   Gelber, R D ^a   Coates, A S ^a   Hans Jorg S ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; FENRETINIDE; FULVESTRANT; GONADORELIN DERIVATIVE; PACLITAXEL; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE;

BIOLOGICAL THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONFERENCE PAPER; GENETIC SUSCEPTIBILITY; HUMAN; LYMPH NODE DISSECTION; ONCOGENE NEU; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SENTINEL LYMPH NODE BIOPSY; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0035884636     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.18.3817     Document Type: Conference Paper

References (84)

1. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women
2. Ovarian ablation in early breast cancer: Overview of the randomised trials
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Polychemotherapy for early breast cancer: An overview of the randomised trials
5. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
6. Meeting highlights: International consensus panel on the treatment of primary breast cancer
7. Environmental and heritable factors in the causation of cancer
8. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer
9. Serum oestradiol and breast cancer risk
10. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: Study of Osteoporotic Fractures Research Group
11. Lessons learned from BRCA 1 and BRCA2
12. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
13. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA 1 mutation carriers
14. Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA 1 or BRCA2 mutations
15. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA 1 or BRCA2 mutations
16. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
17. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P- 1 Study
18. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
19. Chemoprevention options for BRCA1 and BRCA2 mutation carriers
20. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/ BRCA2 mutations more than in other women?
21. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women-Italian tamoxifen prevention study
22. Continuation of the International Breast Cancer Intervention Study (IBIS)
23. Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
24. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study-Hereditary Breast Cancer Clinical Study Group
25. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
26. Selective estrogen receptor modulators: Structure, function, and clinical use
27. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (gw7604) related to tamoxifen
28. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B- 17
29. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: Intraductal carcinoma
30. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
31. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853-EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
32. The influence of margin width on local control of ductal carcinoma in situ of the breast
33. Intraoperative lymphatic mapping and sentinel lymph node dissection in breast cancer
34. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
35. Learning sentinel node biopsy: Results of a prospective randomized trial of two techniques
36. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients
37. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries
38. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
39. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer
40. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
41. Femara (Letrozole) showed significant improvement in efficacy over tamoxifen as first-line treatment in postmenopausal women with advanced breast cancer: The Letrozole International Breast Cancer Study Group
42. Adjuvant treatment of very young women with breast cancer: Need for tailored treatments
43. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5
44. Complete hormonal blockade versus chemotherapy in premenopausal early stage breast cancer patients with positive hormone receptors and 1-3 node-positive tumors: Results of the FASG 06 Trial
45. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group O2 Randomized Trial
46. (Node positive) Breast cancer: Preliminary efficacy, QOL and BMD results from the ZEBRA study - The ZEBRA (Zoladex Early Breast Cancer Research Association) Trialist's Group
47. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
48. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93
49. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up
50. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: Are all CMFs alike? The International Breast Cancer Study Group (IBCSG)
51. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)
52. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
53. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC)
54. Taxanes as adjuvant for breast cancer
55. How to improve timing and duration of adjuvant chemotherapy
56. A prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of the CALGB9082/SWOG9114/NCIC MA-13
57. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial-Scandinavian Breast Group 9401 study
58. Randomized phase III study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
59. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
60. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors: The International Breast Cancer Study Group
61. Better outcome of premenopausal node-positive breast cancer patients treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: Eight year follow-up results of FASG 01
62. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
63. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-Year results from the National Surgical Adjuvant Breast and Bowel Project Trial
64. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy
65. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
66. Costs and benefits of adjuvant chemotherapy for breast cancer: An assessment of patient preferences
67. Patients' view of minimum acceptable benefits from adjuvant hormonal therapy
68. Quality-of-life scores predict outcome in metastatic but not early breast cancer: International Breast Cancer Study Group
69. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
70. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
71. Is the addition of adjuvant chemotherapy always necessary in node negative (N-) postmenopausal breast cancer patients (Pts) who receive tamoxifen (TAM)? First results of IBCSG Trial IX
72. CMF versus CAF with and without Tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup Trial Int 0102
73. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B- 23
74. Systemic adjuvant treatment for premenopausal node-negative breast cancer: The International Breast Cancer Study Group
75. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
76. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI
77. Endocrine profile in breast cancer patients receiving chemotherapy
78. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group
79. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101)
80. Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: A randomised trial by the Cancer Research Campaign (C. R. C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South-East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G. I. V. I. O)
81. Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
82. Tamoxifen (TAM) Vs aminoglutethimide (AG) in breast cancer patients (Pts) previously treated with adjuvant TAM: Preliminary results of a multicentric comparative study
83. Dose and dose intensity of adjuvant chemotherapy for stage 11, node-positive breast carcinoma
84. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial